RevoluGen Announces the Appointment of Sue Charles to Communications Head

London, UK – 1 October 2020  – The UK genomic tools developer, RevoluGen Ltd. (‘RevoluGen or the Company), today announces the appointment of Sue Charles as Head of Corporate Communications and Investor Relations.

She takes on the in-house role at RevoluGen part-time and will assume responsibility for its communications with customer, corporate and financial audiences.

Sue is a highly regarded veteran of the life sciences industry and serves on the board of the UK BioIndustry Association. Most recently she was a Managing Partner at Instinticif Partners leading its global Healthcare and Life Sciences practice, where RevoluGen was a client. 

The appointment reflects the Company’s growth ambitions and maturity. RevoluGen is at the strategic entry point for DNA sequencing and has invented a game-changing technology that extracts highly pure, long-length DNA from cells. With the explosion of DNA sequencing opportunities, including in human and microbial genomics, the market opportunities for RevoluGen’s Fire Monkey/Fire Flower product is large and fast growing.  

With a career in the life sciences sector that spans over three decades, Sue is a recognised entrepreneur and communications strategist. She has founded leading life science communications consultancies in the UK, Germany, USA and Australia, steering their strategic growth and business development. In her past roles as CEO at Northbank Communications and De Facto, she attracted venture finance and led M&A and trade sale transactions. Sue has also spent a period as CEO of a biotech spin out and has provided consultancy service to numerous venture capital firms. She has now transitioned into a portfolio career, including personal communications advisory, through Charles Consultants, alongside consultancy assignments for a number of firms including Consilium Strategic Communications and Scius Communications. She has a first-class degree and MA in Biochemistry from Oxford University, PhD-level research experience in molecular biology at Leicester University and an MBA from Cranfield Business School.

Commenting on her appointment, Sue Charles said “I am looking forward to working closely with the team at RevoluGen, in my first in-house comms role. I have a passion for helping shape the stories and celebrate the successes of companies at the interface of innovation and wealth creation, in healthcare, life sciences and biotech and have had the honour of working with many cutting-edge companies over the years. In particular, I enjoy working with high-science, high-potential organisations with a focus on disruptive technologies in anti-infectives, microbiome, DNA sequencing, and novel therapeutics and diagnostics, so RevoluGen is a perfect fit.”

Welcoming Sue to the team RevoluGen CEO Pieter Haitsma Mulier said "We are all impressed by Sue’s expertise and insight in life sciences communications. She has a depth of knowledge and contacts built over her years in the industry, and her energy and drive has already made a massive difference to our messaging and communications. Sue has been instrumental in the launch of our new website, which better reflects the Company and our offering.” See the new website HERE

- Ends -

About RevoluGen

RevoluGen is a privately held scientific research and development company commercialising molecular tools with a specific focus on rapidly extracting long and pure DNA fragments from cells.

RevoluGen’s Nucleic Acid Isolation and Purification (NAIP) products have particular applications in long-read DNA sequencing for genome assembly and long-range PCR. Fire Monkey significantly improves long-read sequencing results by extracting long-fragment DNA with a simultaneous size selection function built into the protocol that minimises the small-fragment DNA contamination. Used independently, the size selection protocol of Fire Flower can improve the molecular ratio of any extraction kit and is compatible with all sequencing technologies.

The Company headquarters, R&D, manufacturing and direct customer sales and support are based in the UK. RevoluGen serves customers worldwide and has secured agreements with world-leading molecular biology tools companies including Merck KGaA (sales), Cytiva (manufacturing), Tecan (automation) and A4P (logistics).

For more information, please visit www.revolugen.co.uk. Follow us on Twitter and LinkedIN

For more information or to arrange media interviews please contact:

Sue Charles, Head Corporate Communications and Investor Relations, RevoluGen

+44 (0)7968 726585, sue.charles59@outlook.com